# GSK1349572 Relative Bioavailability Study

> **NCT01098513** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 24 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK1349572 formulation AP
- **DRUG:** GSK1349572 formulation AW
- **DRUG:** GSK1349572 formulation AX

## Key facts

- **NCT ID:** NCT01098513
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-06
- **Final completion:** 2010-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01098513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01098513, "GSK1349572 Relative Bioavailability Study". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01098513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*